(1-methylpiperidin-4-yl)methanamine hydrochloride | 1185296-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1-methylpiperidin-4-yl)methanamine hydrochloride
• 英文别名: (1-methylpiperidin-4-yl)methanamine;hydrochloride
• CAS: 1185296-75-6
• 化学式: C₇H₁₆N₂*ClH
• 分子量: 164.678
• InChiKey: XEFFFJHYAWLMRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.71
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1-methylpiperidin-4-yl)methanamine hydrochloride 、 4-(6-bromo-5-(N,N-bis-boc-amino)pyrazin-2-yl)phenol 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以37%的产率得到6-(4-hydroxyphenyl)-1-((1-methylpiperidin-4-yl)methyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
  参考文献：
  名称：

  WO2008/51493

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-Butyl ((1-methylpiperidin-4-yl)methyl)carbamate 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 以1.2 g的产率得到(1-methylpiperidin-4-yl)methanamine hydrochloride
  参考文献：
  名称：

  Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors

  摘要：

  We report here the discovery of a novel series of selective mTOR kinase inhibitors. A series of imidazo[ 4,5-b]pyrazin-2-ones, represented by screening hit 1, was developed into lead compounds with excellent mTOR potency and exquisite kinase selectivity. Potent compounds from this series show >1000-fold selectivity over the related PI3K alpha lipid kinase. Further, compounds such as 2 achieve mTOR pathway inhibition, blocking both mTORC1 and mTORC2 signaling, in PC3 cancer cells as measured by inhibition of pS6 and pAkt (S473). (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.035

文献信息

• Heteroaryl compounds, compositions thereof, and methods of treatment therewith
  申请人：Mortensen Deborah Sue

  公开号：US20090023724A1

  公开（公告）日：2009-01-22

  Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供具有以下结构的杂环芳基化合物：其中R1，R2，L，X，Y，Z，Q，A和B的定义如下，包括有效量的杂环芳基化合物的组合物以及治疗或预防癌症，炎症状况，免疫状况，代谢状况以及通过抑制激酶通路可治疗或预防的状况的方法，包括向需要治疗的患者中给予有效量的杂环芳基化合物。
• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS
  申请人：Mortensen Deborah Sue

  公开号：US20110245245A1

  公开（公告）日：2011-10-06

  Provided herein are Heteroaryl Compounds having the following structure: wherein R 1 , R 2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

  本文提供了具有以下结构的杂环芳基化合物：其中R1、R2、L、X、Y、Z、Q、A和B的定义如下，包括有效量的杂环芳基化合物的组合物，并且治疗或预防癌症、炎症状况、免疫病状况、代谢病状况和通过抑制激酶途径可治疗或预防的病状况的方法包括向需要治疗的患者中施用有效量的杂环芳基化合物。
• HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Signal Pharmaceuticals LLC

  公开号：EP2078016A2

  公开（公告）日：2009-07-15
• Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
  申请人：Signal Pharmaceuticals, LLC

  公开号：EP2090577B1

  公开（公告）日：2017-04-05
• US7981893B2
  申请人：——

  公开号：US7981893B2

  公开（公告）日：2011-07-19